November 23, 2020

The Niche

Knoepfler lab stem cell blog

Platelet Rich Plasma

10 min read

I’m continuing my patient Q&A series of posts and today is questions & answers post #3, which is on platelet-rich plasma, also known as PRP. You can read Q&A #1 on the potential for stem cell clinics to put patients at risk of graft-vs-host disease, and Q&A #2 on whether stem cell transplant recipients and autoimmune patients may be at higher risk of COVID-19. At left you can see an image of a PRP injection. In this case PRP is being injected into a …Read More

3 min read

As I broke the news yesterday, the high-profile fat stem cell clinic firm U.S. Stem Cell (USRM) just lost a groundbreaking court case. Here is the FDA’s official reaction today to the court ruling. Also, since the ruling major media have been covering the court ruling. Here are some examples: From the Washington Post from William Wan and Laurie McGinley we have FDA wins groundbreaking case against for-profit stem cell company. Michael Hiltzik of the LA Times has a blunter headline. Backing the FDA, a …Read More

2 min read

Stem cell biotech company Bioheart ($BHRT) has had a rough 2015 so far. Could this year be a decisive, negative tipping point for the company? It has a number of clinical trials going, but from my view things seem increasingly uncertain. An oddity amongst stem cell biotechs, Bioheart and its leadership have at times seemed to toy with what some might view as controversial projects. Kristin Comella, CSO of Bioheart, has played a major role in other ventures including in the past with the Ageless Institute, a stem …Read More

7 min read

I invited the Chief Scientific Officer (CSO) of Bioheart, Kristin Comella, to do an interview after hearing some buzz that this could be a critical time for the company and that it might have been recently visited by the FDA. Note that Comella not just Bioheart CSO, but also the primary instructor for physician training in stem cell methods offered by the company US Stem Cell Training. Can you update us on how Bioheart is doing with its clinical trials/INDs? Comella: Our completed clinical trials of …Read More